SecBot SecBot
6-K ·Filed Apr 29, 2026

AZN

ASTRAZENECA PLC
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001654954-26-004047
Notable filing: 6-K
Actionable Insight ▲ Bullish

Solid earnings beat with broad-based growth in Oncology and Rare Disease offsets CVRM weakness. The CSPC obesity deal adds long-term pipeline optionality but near-term R&D spend will increase. Guidance reaffirmation supports current valuation. Watch for H1 2026 results on 27 July 2026 and upcoming Phase III readouts for Enhertu (DESTINY-Breast05) and Calquence (AMPLIFY).

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$185.00
T+0 close · Apr 29, 2026 · via day close
Latest settled
−9.04%
T+60 · $168.27
Vs SPY
−12.78%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 29 $185.00entry
  2. T+1 · 7mo ago +1.29%α +0.27% · $187.39
  3. T+5 · 7mo ago −0.10%α −3.21% · $184.81
  4. T+20 · 6mo ago +0.18%α −5.86% · $185.34
  5. T+60 · 4mo ago −9.04%α −12.78% · $168.27

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca reported strong Q1 2026 results with Total Revenue up 8% CER to $15.3B, driven by Oncology (+16% CER) and Rare Disease (+15% CER). Core EPS grew 5% CER to $2.58, and FY 2026 guidance for mid-to-high single-digit revenue growth and low double-digit Core EPS growth was reaffirmed. The company also closed a $1.2B upfront collaboration with CSPC for obesity/diabetes therapies and reported positive Phase III readouts for tozorakimab and efzimfotase alfa.

Key Facts

  • Total Revenue $15,288M, up 8% CER (actual +13%)
  • Reported EPS $1.99, up 8% CER; Core EPS $2.58, up 5% CER
  • Oncology revenue +16% CER, Rare Disease +15% CER
  • CVRM revenue declined 6% CER, primarily due to Farxiga generic competition
  • FY 2026 guidance reaffirmed: mid-to-high single-digit revenue growth, low double-digit Core EPS growth
  • Closed $1.2B upfront collaboration with CSPC for obesity/type 2 diabetes therapies
  • Positive Phase III data for tozorakimab (COPD) and efzimfotase alfa (HPP); Enhertu patent litigation resolved favorably
  • Net debt increased to $25.9B, driven by financing activities and business development payments

Financial Impact

Q1 2026 revenue $15.3B, operating profit $4.2B (reported) and $5.4B (core); Core EPS $2.58, up 5% CER; $1.2B upfront for CSPC deal and $100M for Jacobio

revenueepsdebtr&d spending

Risk Factors

  • Generic competition pressuring CVRM revenue, especially Farxiga and Brilinta
  • Increased leverage from $1.2B CSPC upfront and $1.99B new debt issuance
  • Litigation overhang from 340B antitrust appeal and Texas qui tam trial scheduled for August 2026

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
81% bullish (36 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-004047
Document: 0001654954-26-004047-index-headers.html0001654954-26-004047
Document: 0001654954-26-004047-index.html0001654954-26-004047
Document: 0001654954-26-004047.txt0001654954-26-004047

Track record

77 reports on AZN

Performance horizon

19 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
  5. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Wed (11h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 29, 2026